A Canada-US-Hongkong based biotech has appointed Aagami to support their investment and partnering needs for their ‘Single (monovalent) vaccine for ...
Published : 23 Feb 2023
Read MoreAagami completed a very fruitful JPM week and Biotech Showcase 2023 in San Francisco (January 9–11) with over 40 one-on-one strategic meetings with ...
Published : 16 Jan 2023
Read MoreAagami CEO Dinesh Jain and VP Godwyn Francis completed a very fruitful business trip to Republic of Korea in December 2022. Aagami was a par...
Published : 15 Dec 2022
Read MoreAagami are glad to announce that their Japanese client has given a new assignment, to seek partnerships for one more asset in their pipeline. Aagami a...
Published : 22 Nov 2022
Read MoreBio2Device Group (B2DG), CA have organized an event where Aagami CEO Dinesh Jain will be speaking on "How To Do Cross Border Partnering in Lifescience...
Published : 14 Nov 2022
Read MoreAagami VP Godwyn Francis participated in “Global Bio & Pharma Plaza 2022” This partnering event was held from Oct 12th to 13th, 2022 in S...
Published : 28 Oct 2022
Read MoreAagami successfully completed Bio-Japan 2022 (October 11-14) with more than 25 fruitful meetings. Akshay Bavaria, BD Manager led the digital part...
Published : 22 Oct 2022
Read MoreNFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addict...
Published : 10 Oct 2022
Read MoreFrench Biotech client awarded yet another contract extension to Aagami. Client is a publicly listed company developing a drug for smoking cessation.&n...
Published : 15 Jul 2022
Read MoreWe are glad to announce that Aagami is attending the International Life Sciences Partnering Conference – BIO-Europe® 2022 (October 2...
Published : 11 Jul 2022
Read More